/
The Company is a contract development and manufacturing organization that specializes in single-use and single-patient medical devices. The Company is a vital link in the medical device supply chain and a valued outsourcing partner to many of the world's top medical device manufacturers.
$242.05
$14.69 (-5.72%)
EOD Jul 17, 2026
15.32% operating margin is respectable but not wide. ROIC at 13.86%. Suggests the business covers its cost of capital, but doesn't point to a wide moat.
Revenue grew 19.5%, still solid.
At 28x earnings, the current multiple leaves limited room for execution misses or growth deceleration.
27.6x earnings. Not cheap, the quality is already reflected in the price. Upside from here requires either margin expansion or growth re-acceleration, not just continuation.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
$609M
▲ +19.5% YoY
Net Income (TTM)
$69M
▲ +15.8% YoY
Op. Margin
15.21%
▼ -0.7pp YoY
ROIC
13.40%
▼ -1.3pp YoY
Cash Flow & Balance Sheet
FCF
N/A
Op. Cash Flow (TTM)
$81M
▲ +38.0% YoY
Net Debt
$136M
Cash & Equiv.
$20M
5Y CAGR: +27.4%
5Y CAGR: +17.5%
Continue Research
At a P/E of 27.6, UFP Technologies (UFPT) trades below a two-stage DCF intrinsic value of about $351.07 per share, so at $242.05 the stock looks undervalued (45.0% below estimated intrinsic value). A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, UFP Technologies scores 36/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full methodology. This is analysis, not investment advice.
Intrinsiqq's two-stage DCF estimates an intrinsic value of about $351.07 per share for UFPT, projecting its recent free cash flow forward with a growth rate that fades toward a long-run rate and discounting it back to today. Applying a 25% margin of safety gives a more conservative fair-value entry around $263.30. At today's $242.05, that puts the stock about 45.0% below estimated intrinsic value. The result is sensitive to the growth and discount-rate inputs, so it is best to run conservative, base and optimistic cases. You can adjust all of them yourself with the sliders on the DCF tab.
UFP Technologies scores 36 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a 15.2% operating margin and a 13.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. UFPT currently trades below its estimated intrinsic value and scores 36/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.